Breaking News Instant updates and real-time market news.

RIGL

Rigel Pharmaceuticals

$3.35

0.01 (0.30%)

14:34
04/12/18
04/12
14:34
04/12/18
14:34

Rigel gives up gains after saying approval posted in error

Shares of Rigel Pharmaceuticals gave back a large part of today's gains after the company told Bloomberg that the approval posted on its Investors webpage was done in error. The company has not received notice from the FDA on the approval of Tavalisse, it said to the news agnecy. The FDA action date for the drug is April 17. Rigel shares, which jumped as high as 40% on the day, are now only up 10% to $3.71.

  • 17

    Apr

RIGL Rigel Pharmaceuticals
$3.35

0.01 (0.30%)

04/03/18
JEFF
04/03/18
NO CHANGE
Target $5
JEFF
Buy
Rigel selloff on IgAN trial miss overdone, says Jefferies
Jefferies analyst Eun Yang called the fact that Rigel Pharmaceuticals' Phase 2 trial evaluating fostamatinib in IgAN failed to meet its primary endpoint "somewhat disappointing," but also said the news does not change his valuation or view on the approvability in patients with chronic or persistent immune thrombocytopenia. The analyst, who said the company is "completely optimistic" for timely approval of fostamatinib in the ITP indication by the PDUFA date of April 17, keeps a Buy rating and $5 price target on Rigel shares, calling today's selloff "overdone."
04/03/18
HCWC
04/03/18
NO CHANGE
Target $6.7
HCWC
Buy
H.C. Wainwright says Rigel's 'small setback' a buying opportunity ahead of PDUFA
H.C. Wainwright analyst Joseph Pantginis called news that Rigel Pharmaceuticals' Phase 2 study of fostamatinib in patients with IgA nephropathy did not meet its primary endpoint a "small setback" for the company and an opportunity for investors. He believes today's selling pressure is an overreaction, adding that "brighter skies may be tomorrow, almost literally," with the company's PDUFA date for fostamatinib in ITP coming on April 17. Pantginis reiterates a Buy rating on Rigel and trimmed his price target on the stock to $6.70 from $7.
04/04/18
JEFF
04/04/18
NO CHANGE
Target $5
JEFF
Buy
Rigel selloff yesterday on failed study overdone, says Jefferies
Jefferies analyst Eun Yang says that while yesterday's Phase 2 trial results in IgA nephropathy, fostamatinib's third indication, is "somewhat disappointing," it does not change her valuation or upcoming approvability in first indication immune thrombocytopenic purpura. The analyst views the selloff yesterday in shares of Rigel Pharmaceuticals as overdone. She believes the failed study has no bearing on the approval in ITP, which has an FDA action date of April 17. Yang reiterates a Buy rating on Rigel with a $5 price target.
04/09/18
JPMS
04/09/18
NO CHANGE
JPMS
Overweight
Rigel Pharmaceuticals shares can rally 80% on FDA approval, says JPMorgan
JPMorgan analyst Anupam Rama continues to see a favorable risk/reward profile on Rigel Pharmaceuticals heading into the April 17 FDA action date for Tavalisse in immune thrombocytopenia. The analyst sees a "high probability" of approval for Tavalisse and 50%-80% share upside on the news, "assuming no major surprises in the label." The approval is setting up to be a "true binary event," with potential share downside in the 65%-80% range, Rama tells investors in a research note. He keeps an Overweight rating on Rigel shares.

TODAY'S FREE FLY STORIES

C

Citi

$64.19

0.69 (1.09%)

14:08
11/15/18
11/15
14:08
11/15/18
14:08
Hot Stocks
Citi reports October credit loss 2.63% vs. 2.42% last month »

Reports October 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

  • 15

    Apr

  • 13

    Jul

DPZ

Domino's Pizza

14:04
11/15/18
11/15
14:04
11/15/18
14:04
Recommendations
Domino's Pizza analyst commentary  »

Stephens says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

ZIOP

Ziopharm

$2.85

0.17 (6.34%)

14:04
11/15/18
11/15
14:04
11/15/18
14:04
Upgrade
Ziopharm rating change  »

Ziopharm upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSI

Motorola Solutions

$129.48

0.715 (0.56%)

14:02
11/15/18
11/15
14:02
11/15/18
14:02
Hot Stocks
Motorola Solutions boosts quarterly dividend by 10% to 57c »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

FB

Facebook

$143.17

-1.08 (-0.75%)

13:58
11/15/18
11/15
13:58
11/15/18
13:58
Hot Stocks
Facebook board admits to pushing CEO, COO to 'move faster' on interference »

The board of Facebook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

SPY

SPDR S&P 500 ETF Trust

$271.90

1.71 (0.63%)

, SPX

S&P 500

$0.00

(0.00%)

13:57
11/15/18
11/15
13:57
11/15/18
13:57
Periodicals
U.S., China step up effort to strike G20 truce on trade, FT reports »

The U.S. and China have…

SPY

SPDR S&P 500 ETF Trust

$271.90

1.71 (0.63%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:55
11/15/18
11/15
13:55
11/15/18
13:55
General news
U.S. equities snapped back into the green »

U.S. equities snapped…

IAC

IAC

$180.83

0.23 (0.13%)

13:50
11/15/18
11/15
13:50
11/15/18
13:50
Hot Stocks
Rock Holdings acquires Dictionary.com, Thesaurus.com from IAC »

Dan Gilbert's Rock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLR

Fluor

$46.20

1.49 (3.33%)

13:48
11/15/18
11/15
13:48
11/15/18
13:48
Conference/Events
Fluor to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

RCMT

RCM Technologies

$4.03

0.03 (0.75%)

13:48
11/15/18
11/15
13:48
11/15/18
13:48
Hot Stocks
RCM Technologies announces acquisition of Thermal Kinetics, terms not disclosed »

RCM Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RARE

Ultragenyx

$51.33

2.92 (6.03%)

13:45
11/15/18
11/15
13:45
11/15/18
13:45
Conference/Events
Ultragenyx haqs a conference call hosted by JPMorgan »

JPMorgan Analyst Kasimov…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 27

    Nov

  • 27

    Nov

VIAB

Viacom

$31.87

0.07 (0.22%)

, VIA

Viacom

$35.23

-0.1 (-0.28%)

13:41
11/15/18
11/15
13:41
11/15/18
13:41
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

VIAB

Viacom

$31.87

0.07 (0.22%)

VIA

Viacom

$35.23

-0.1 (-0.28%)

HP

Helmerich & Payne

$59.45

1.15 (1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

  • 16

    Nov

  • 16

    Nov

  • 04

    Dec

NVDA

Nvidia

$201.85

4.63 (2.35%)

, AMAT

Applied Materials

$34.94

1.35 (4.02%)

13:41
11/15/18
11/15
13:41
11/15/18
13:41
Earnings
Notable companies reporting after market close »

Notable companies…

NVDA

Nvidia

$201.85

4.63 (2.35%)

AMAT

Applied Materials

$34.94

1.35 (4.02%)

POST

Post Holdings

$91.15

-0.43 (-0.47%)

WSM

Williams-Sonoma

$60.67

-1.09 (-1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 16

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

PPL

PPL Corp.

$30.56

-1.63 (-5.06%)

13:35
11/15/18
11/15
13:35
11/15/18
13:35
Options
PPL Corp. put volume heavy and directionally bearish »

Bearish flow noted in PPL…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$19.07

-6.59 (-25.68%)

13:32
11/15/18
11/15
13:32
11/15/18
13:32
Recommendations
PG&E analyst commentary  »

PG&E recent weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSGN

MSG Networks

$25.48

-0.53 (-2.04%)

13:20
11/15/18
11/15
13:20
11/15/18
13:20
Hot Stocks
MSG Networks announces sponsorship deal for Devils broadcasts with William Hill »

MSG Networks and William…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:20
11/15/18
11/15
13:20
11/15/18
13:20
General news
Atlanta Fed's Q4 GDPNow estimate was trimmed to 2.8% »

Atlanta Fed's Q4…

CVS

CVS Health

$79.23

-0.69 (-0.86%)

, AET

Aetna

$207.58

-0.58 (-0.28%)

13:17
11/15/18
11/15
13:17
11/15/18
13:17
Hot Stocks
California regulator approves CVS's acquisition of Aetna »

The California Department…

CVS

CVS Health

$79.23

-0.69 (-0.86%)

AET

Aetna

$207.58

-0.58 (-0.28%)

WCG

WellCare

$246.88

-4.14 (-1.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
11/15/18
11/15
13:17
11/15/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCO

Clear Channel Outdoor

$5.51

0.19 (3.57%)

, OUT

Outfront Media

$21.01

0.32 (1.55%)

13:16
11/15/18
11/15
13:16
11/15/18
13:16
Periodicals
Clear Channel Outdoor rises after JCDecaux CEO expresses takeover interest »

JCDecaux (JCDXF) CEO…

CCO

Clear Channel Outdoor

$5.51

0.19 (3.57%)

OUT

Outfront Media

$21.01

0.32 (1.55%)

JCDXF

JCDecaux

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
11/15/18
11/15
13:16
11/15/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
11/15/18
11/15
13:15
11/15/18
13:15
General news
Atlanta Fed dove Bostic wants to "proceed cautiously" »

Atlanta Fed dove Bostic…

FB

Facebook

$142.11

-2.14 (-1.48%)

13:12
11/15/18
11/15
13:12
11/15/18
13:12
Hot Stocks
Facebook comments on progress enforcing community standards »

Facebook comments on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

CCO

Clear Channel Outdoor

$5.21

-0.11 (-2.07%)

, OUT

Outfront Media

$20.64

-0.05 (-0.24%)

13:11
11/15/18
11/15
13:11
11/15/18
13:11
Periodicals
Breaking Periodicals news story on Clear Channel Outdoor, Outfront Media »

JCDecaux has expressed…

CCO

Clear Channel Outdoor

$5.21

-0.11 (-2.07%)

OUT

Outfront Media

$20.64

-0.05 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

NICE

Nice Systems

$110.77

0.48 (0.44%)

13:11
11/15/18
11/15
13:11
11/15/18
13:11
Conference/Events
Nice Systems management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.